{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["UCART123v1.2"]],"indication":"relapsed/refractory acute myeloid leukemia","name":"AMELI-01","nct_id":"NCT03190278","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ameli-01-nct03190278. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AMELI-01","arms":[{"description":"UCART123v1.2 tested at several dose levels with different lymphodepletion regimens to establish Maximum Tolerated Dose (MTD) and identify Recommended Phase 2 Dose (RP2D)\n\nDose Expansion: UCART123v1.2 administered at the RP2D determined from the dose escalation phase","label":"Dose Escalation","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-12","type":"ESTIMATED"},"conditions":["Relapsed/Refractory Acute Myeloid Leukemia"],"enrollment":{"count":29,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"UCART123v1.2","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2025-08-07","lead_sponsor":"Cellectis S.A.","official_title":"Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2024-12-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Incidence of adverse events (AE)/serious adverse events (SAE)/Dose Limiting Toxicities (DLT) [Safety and Tolerability]","timeFrame":"24 Months"},{"measure":"Dose escalation and expansion part: Occurrence of DLTs","timeFrame":"Up to Day 28 post last UCART123v1.2 infusion"}],"references":[],"start_date":{"date":"2017-06-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","url":"https://clinicaltrials.gov/study/NCT03190278"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ameli-01-nct03190278"}